New hope for tiniest lungs: IVIG trial aims to help preemies breathe
NCT ID NCT06925360
Summary
This study is testing whether a treatment called intravenous immunoglobulin (IVIG) can help control a serious lung disease in very premature babies. It will involve about 20 infants born between 25 and 30 weeks of pregnancy who show signs of the disease. The main goal is to see if the IVIG treatment helps babies survive without needing ongoing breathing support by 36 weeks of corrected age.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
International Peace Maternity and Child Health Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.